Literature DB >> 12525527

Osteosarcoma of the pelvis: experience of the Cooperative Osteosarcoma Study Group.

Toshifumi Ozaki1, Silke Flege, Matthias Kevric, Norbert Lindner, Rainer Maas, Günter Delling, Rudolf Schwarz, Arthur R von Hochstetter, Mechthild Salzer-Kuntschik, Wolfgang E Berdel, Heribert Jürgens, G Ulrich Exner, Peter Reichardt, Regine Mayer-Steinacker, Volker Ewerbeck, Rainer Kotz, Winfried Winkelmann, Stefan S Bielack.   

Abstract

PURPOSE: To define patients and tumor characteristics as well as therapy results, patients with pelvic osteosarcoma who were registered in the Cooperative Osteosarcoma Study Group (COSS) were analyzed. PATIENTS AND METHODS: Sixty-seven patients with a high-grade pelvic osteosarcoma were eligible for this analysis. Fifteen patients had primary metastases. All patients received chemotherapy according to COSS protocols. Thirty-eight patients underwent limb-sparing surgery, 12 patients underwent hemipelvectomy, and 17 patients did not undergo definitive surgery. Eleven patients received irradiation to the primary tumor site: four postoperatively and seven as the only form of local therapy.
RESULTS: Local failure occurred in 47 of all 67 patients (70%) and in 31 of 50 patients (62%) who underwent definitive surgery. Five-year overall survival (OS) and progression-free survival rates were 27% and 19%, respectively. Large tumor size (P =.0137), primary metastases (P =.0001), and no or intralesional surgery (P <.0001) were poor prognostic factors. In 30 patients with no or intralesional surgery, 11 patients with radiotherapy had better OS than 19 patients without radiotherapy (P =.0033). Among the variables, primary metastasis, large tumor, no or intralesional surgery, no radiotherapy, existence of primary metastasis (relative risk [RR] = 3.456; P =.0009), surgical margin (intralesional or no surgical excision; RR = 5.619; P <.0001), and no radiotherapy (RR = 4.196; P =.0059) were independent poor prognostic factors.
CONCLUSION: An operative approach with wide or marginal margins improves local control and OS. If the surgical margin is intralesional or excision is impossible, additional radiotherapy has a positive influence on prognosis.

Entities:  

Mesh:

Year:  2003        PMID: 12525527     DOI: 10.1200/JCO.2003.01.142

Source DB:  PubMed          Journal:  J Clin Oncol        ISSN: 0732-183X            Impact factor:   44.544


  90 in total

1.  Comparison of pirarubicin-based versus gemcitabine-docetaxel chemotherapy for relapsed and refractory osteosarcoma: a single institution experience.

Authors:  Aina He; Weixiang Qi; Yujing Huang; Yuanjue Sun; Zan Shen; Hui Zhao; Yumei Yang; Yang Yao
Journal:  Int J Clin Oncol       Date:  2012-04-26       Impact factor: 3.402

2.  Orthopaedic tumors: What problems are we solving, and are universities and major medical centers doing enough?

Authors:  Mohamed Mediouni; Daniel R Schlatterer
Journal:  J Orthop       Date:  2017-05-04

Review 3.  State-of-the-art approach for bone sarcomas.

Authors:  Andreas F Mavrogenis; Andrea Angelini; Christos Vottis; Emanuela Palmerini; Eugenio Rimondi; Giuseppe Rossi; Panayiotis J Papagelopoulos; Pietro Ruggieri
Journal:  Eur J Orthop Surg Traumatol       Date:  2014-05-03

4.  Proton-based radiotherapy for unresectable or incompletely resected osteosarcoma.

Authors:  I Frank Ciernik; Andrzej Niemierko; David C Harmon; Wendy Kobayashi; Yen-Lin Chen; Torunn I Yock; David H Ebb; Edwin Choy; Kevin A Raskin; Norbert Liebsch; Francis J Hornicek; Thomas F Delaney
Journal:  Cancer       Date:  2011-03-29       Impact factor: 6.860

Review 5.  [Osteosarcoma and chondrosarcoma of the pelvis and lower extremities].

Authors:  W K Guder; J Hardes; G Gosheger; M Nottrott; A Streitbürger
Journal:  Chirurg       Date:  2015-10       Impact factor: 0.955

6.  Axial skeletal osteosarcoma: a 25-year monoinstitutional experience in children and adolescents.

Authors:  Cristina Meazza; Roberto Luksch; Primo Daolio; Marta Podda; Alessandro Luzzati; Alessandro Gronchi; Antonina Parafioriti; Lorenza Gandola; Paola Collini; Andrea Ferrari; Michela Casanova; Monica Terenziani; Filippo Spreafico; Daniela Polastri; Veronica Biassoni; Elisabetta Schiavello; Emilia Pecori; Maura Massimino
Journal:  Med Oncol       Date:  2014-02-21       Impact factor: 3.064

7.  Osteosarcoma of the pelvis: outcome analysis of surgical treatment.

Authors:  Bruno Fuchs; Nathan Hoekzema; Dirk R Larson; Carrie Y Inwards; Franklin H Sim
Journal:  Clin Orthop Relat Res       Date:  2008-10-15       Impact factor: 4.176

8.  Anthracycline causes impaired vascular endothelial function and aortic stiffness in long term survivors of childhood cancer.

Authors:  Zoltan Jenei; Edit Bárdi; Mária Tünde Magyar; Agnes Horváth; György Paragh; Csongor Kiss
Journal:  Pathol Oncol Res       Date:  2012-12-16       Impact factor: 3.201

9.  Computer-assisted resection and reconstruction of pelvic tumor sarcoma.

Authors:  Pierre-Louis Docquier; Laurent Paul; Olivier Cartiaux; Christian Delloye; Xavier Banse
Journal:  Sarcoma       Date:  2010-11-28

10.  Sorafenib blocks tumour growth, angiogenesis and metastatic potential in preclinical models of osteosarcoma through a mechanism potentially involving the inhibition of ERK1/2, MCL-1 and ezrin pathways.

Authors:  Ymera Pignochino; Giovanni Grignani; Giuliana Cavalloni; Manuela Motta; Marta Tapparo; Stefania Bruno; Alessia Bottos; Loretta Gammaitoni; Giorgia Migliardi; Giovanni Camussi; Marco Alberghini; Bruno Torchio; Stefano Ferrari; Federico Bussolino; Franca Fagioli; Piero Picci; Massimo Aglietta
Journal:  Mol Cancer       Date:  2009-12-10       Impact factor: 27.401

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.